Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

recombinant modified vaccinia Ankara-5T4 vaccine

A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the 5T4 fetal oncoprotein (MVA-h5T4). Vaccination with recombinant modified vaccinia Ankara-5T4 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing 5T4 fetal oncoprotein antigen, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attentuated, replication-defective vaccinia strain incapable of virion assembly.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:recombinant MVA-5T4 vaccine
recombinant pox virus encoding 5T4 vaccine
vaccinia-5T4 antigen vaccine
US brand name:TroVax
Foreign brand name:TroVax
Abbreviation:rV-5T4 VAC
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search